As previously reported, BofA double upgraded Regeneron (REGN) to Buy from Underperform with a price target of $860, up from $627. The firm’s more bullish view is driven by multiple factors, including the fact that its prior Underperform thesis around Eylea SD has played out as consensus estimates have come down. In addition, the firm is more bullish on Eylea HD’s potential in light of multiple label updates and its estimates are now “meaningfully higher” than consensus, the analyst tells investors. The firm also sees potential for further upside from Dupixent and potential upside from the pipeline in 2026.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron upgraded to Buy from Underperform at BofA
- Sanofi and Regeneron Expand Dupilumab’s Real-World Footprint in Chronic Urticaria
- Regeneron Advances Phase 3 Antibody Trial in Birch Pollen Eye Allergy: What Investors Should Know
- Regeneron, Sanofi get marketing authorization for Dupixent from MHLW in Japan
- Alvotech, Teva reach settlement and license agreement with Regeneron for AVT06